Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CECP Chemotherapy for AIDS-Related Hodgkin's Disease
NCT00003114Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Jul 1997
- Primary completion
- Jun 2002
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lomustine, etoposide, cyclophosphamide and procarbazine in Hodgkin lymphoma (HL), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Objective Response Rate, Response Duration and 1 more. Started Jul 1997; status: completed.
02
Drugs
lomustineetoposidecyclophosphamideprocarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00003114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003114.